Clinical Trial

Evaluation of cholecalciferol (VitD3) supplementation in patients with multiple myeloma (MM) before transplantation and in combination with lenalidomide maintenance

Participants are eligible for this study if they are diagnosed with a cancer called multiple myeloma, are already planned to receive an autologous stem cell transplant, and have low vitamin D level.The research is being done to determine if higher dose of vitamin D helps patients with multiple myeloma who are undergoing an autologous stem cell transplant. It is known that low levels of vitamin D are common in patients with multiple myeloma and that vitamin D plays a role within the immune system. It is unknown if higher level of vitamin D can help patients more. The purpose of this study is to see if higher vitamin D doses as compared to regular vitamin D doses leads to better outcomes. This means that patients who choose to participate in this study will receive either normal vitamin D dose or a higher dose. The researchers will looks at how each participant responds to treatment, how long they live, their vitamin D levels, and side effects of the medication. Participants will still receive their standard treatment and monitoring for their disease of multiple myeloma while participating in this research. The research study requires laboratory blood draws to look at vitamin D levels in the blood.

• Lymphatic System
• Autologous Stem Cell Transplant
• Cancer
• Lenalidomide
• Multiple Myeloma
• Oncology
• Vitamin D